A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis
Status:
RECRUITING
Trial end date:
2026-07-30
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double-blinded, parallel-group Phase III clinical study to compare the clinical efficacy, safety, and immunogenicity of 9MW0311 and Prolia in Chinese postmenopausal women with osteoporosis at high risk for fracture.